As a result of the Merger (as defined in Item 2.01 of this Current Report on Form 8-K)
- Form
- 8-K
- Filed
- Period
- Importance
- Major
- Accession
- 0001193125-23-233448
- Document
- 8-K
- Exhibit 4.1
- Warrants or notes
- Exhibit 4.2
- Warrants or notes
- Exhibit 10.1
- Material contract
- Exhibit 10.2
- Material contract
- Exhibit 10.3
- Material contract
- Exhibit 10.4
- Material contract
- Exhibit 10.5
- Material contract
- Exhibit 10.6
- Material contract
- Exhibit 99.1
- Press release
- Exhibit 10.7
- Material contract
- Signs a material agreement (1.01)
- Completes an acquisition or sale of assets (2.01)
- Sells unregistered shares (3.02)
- Changes shareholder rights (3.03)
- Changes its auditor (4.01)
- Reports a change in control (5.01)
- Reports an executive or board change (5.02)
- Amends its charter or bylaws (5.03)
- Changes its ethics code (5.05)
- Makes a Regulation FD disclosure (7.01)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Stoke Therapeutics STOK public float $592M, Jun 30, 2025
- Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
- Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
- Anaptysbio ANAB public float $633M, Dec 31, 2025
- Evolus EOLS public float $560M, Jun 30, 2025